Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers develop mouse model of Rett syndrome

19.07.2002


Studies might improve understanding of leading cause of mental retardation in girls

By studying gene mutations in patients with the complex set of behavioral and neurological symptoms that accompany Rett syndrome, Howard Hughes Medical Institute investigator Huda Zoghbi and her colleagues at Baylor College of Medicine have designed a mouse model that faithfully recapitulates the disease down to its distinctive hand-wringing behavior. The development of the mouse, reported in the July 18, 2002 issue of the journal Neuron, provides a springboard into the study of Rett syndrome, the leading cause of mental retardation in girls.

First recognized as a syndrome in the 1980s, the disorder affects one in 10,000-15,000 girls. It is particularly devastating for families with affected children because infants are seemingly normal at birth and achieve the usual developmental milestones for the first few months of life. Then, as the infant reaches toddlerhood, a sudden and dramatic decline in physical and mental capabilities takes hold, accompanied by onset of seizures, irregular breathing, awkward gait, and hand-wringing.

"I know of no other neurological disease that gives this distinctive stereotypic behavior -- this hand-wringing these girls do basically all the time they are awake," said Zoghbi. "With this mouse model we can now ask, ’Why is that?’"

Zoghbi has been studying Rett syndrome since the mid-1980s, when she first encountered patients with the disorder as a neurology fellow and decided to search for the gene responsible for the disorder. She reasoned that the gene must be on the X chromosome, the female sex chromosome, and it must also be essential because there had been no males reported to have the syndrome. (Since males have only one X chromosome, mutations that knock out the gene’s function could be lethal at an embryonic stage.) In females, there are two copies of the X chromosome, but in each cell only one of the two X chromosomes is active. The scientists reasoned that if enough cells are "normal," they can compensate for the mutated gene.

After 14 years of searching, a scientist in Zoghbi’s lab found that a gene called MECP2 was mutated in the Rett Syndrome patients they studied. Earlier research suggested that the MeCP2 protein was responsible for making sure that genes the cell has marked with a molecular tag, called a methyl group, are silenced. The MeCP2 protein latches on to these methyl groups and prevents them from being translated into protein.

How MeCP2’s molecular role translates into a neurological disorder is still not clear. Ever since a diagnostic test for the gene mutation was developed, however, there has been a flood of new information about the prevalence of the disorder. This information reveals that mutations in the MECP2 gene can take a wide variety of forms.

"We now know of cases of classic autism and schizophrenia that are caused by mutations in this gene," said Zoghbi. "The clinical spectrum is so broad that we don’t know the true prevalence of this mutation." She estimates that the mutation may be twice as common as is currently thought, with perhaps one in 10,000 children affected.

What is clear so far is that the MECP2 gene, which resides at the end of the long arm of the human and mouse X chromosome, plays a vital role in fine-tuning the developing nervous system during a crucial stage when infants are learning to sit up, walk, and begin language acquisition, said Zoghbi.

To understand the molecular details of what goes wrong, the scientists first needed to create a mouse model of the disorder. The first attempt at a mouse model, in which the MECP2 gene was deleted completely, resulted in severe disease and early death. Zoghbi and her colleagues sought to create a model that would more closely mimic the progression of the human disorder. So, they studied the various mutations that had been found in patients to design a mutant mouse that would produce a partially functional protein. The result was a mouse that mimics many of the aspects of the disease observed in humans.

Using the mouse model, the scientists will probe how the MeCP2 protein affects brain function at a crucial developmental stage. "The second part of the story is really in discovering what this protein is doing in the brain," said Zoghbi. "It may be that at a certain developmental stage, the brain suddenly requires the function of this protein. In humans, by birth a lot of the hardwiring has already happened. Infancy is a critical time as life experiences refine synaptic function and strengthen synapses. Experiences fine tune the brain. Perhaps more complex tasks require the input of this protein and its loss is now instrumental. Things fall apart and people regress. Perhaps key genes that are important at certain times are not put in place. We don’t know the mechanism but having this mouse model will allow us to ask these questions."

Zoghbi is hopeful that studying the mouse model will also have implications for treatment of patients diagnosed with Rett Syndrome.

"As development progresses, what we encounter -- our experiences -- may also change how the brain responds. This may account for individual variation in disease severity," she said. "It may be that enrichment of the environment or exposure to certain stimuli may give affected children more milestones. I could envision that with interventional studies in mice, we may identify pathways that could lead to behavioral or pharmacological approaches that may provide at least symptomatic relief."

Jim Keeley | EurekAlert

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

Decoding cement's shape promises greener concrete

08.12.2016 | Materials Sciences

Will Earth still exist 5 billion years from now?

08.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>